CYP3A4

CYP3A4 is a major human cytochrome P450 enzyme that drives oxidative xenobiotic metabolism and contributes substantially to interindividual variability in drug pharmacokinetics and response^[1]. Mechanistically, CYP3A4 belongs to the CYP3A subfamily, which metabolizes diverse drugs, endogenous substrates, and nonpharmaceutical xenobiotics through broad substrate recognition and inducible expression^[1][2]. Regulation of this pathway depends strongly on pregnane X receptor (PXR), because PXR modulates xenobiotic metabolism primarily through regulation of CYP3A4 expression^[3]. In disease-relevant and experimental contexts, CYP3A enzymes participate in physiological regulation of endogenous compounds and in pathological processes, making CYP3A4 useful for pharmacology, toxicology, and disease-model research^[2]. Compared with CYP3A5, CYP3A4-mediated metabolism predominated for many tested compounds, while CYP3A5 showed meaningful activity for selected drugs and may matter in CYP3A5-expressing populations^[4]. CYP3A4 also showed stronger inhibitory sensitivity than CYP3A5 for most compounds tested, including greater time-dependent inhibition, supporting isoform-aware inhibitor design and drug-drug interaction assessment^[4]. For experimental applications, midazolam 1′-hydroxylation and testosterone 6β-hydroxylation remain practical CYP3A4/5 marker reactions for in vitro inhibition studies^[5].